智通财经12月21日讯（编辑 笠晨）近年来A股上市公司分红意愿显著提升，市场分红生态持续优化，呈 现出分红总额、参与分红公司数量占比以及年内多次分红公司数量逐年递增的趋势。choice数据统计， 截至发稿，以股权登记日计算，今年以来A股上市公司现金分红总额达到2.61万亿元，已超过2024年全 年，创出历史新高。 Wind数据显示，今年以来，A股上市公司迈瑞医疗、三七互娱、御银股份和玲珑轮胎分红次数均为三 次。山东路桥、雅戈尔、深圳华强、奕帆传动、陕国投A、鱼跃医疗、行动教育、南山铝业、隆扬电 子、艾融软件、分众传媒、药明康德、百龙创园、吉比特、华宝股份、新坐标、龙佰集团、远翔新材、 华明装备、卓创资讯、九强生物、金帝股份、开普检测、西部证券、海希通讯、开能健康、金能科技、 金岭矿业、国光股份和吉电股份分红次数均为两次。具体情况如下图： | 证券简称 | 分红总额 | 分红次数 | Wind行业 | | --- | --- | --- | --- | | | (亿元) | | | | 三七互娱 | 13. 86 | 3 | 传媒 | | 玲珑轮胎 | 3.59 | 3 | 汽车与零配件 | | 迈瑞医疗 | ...

Investment Rating - The report maintains a positive outlook on the insomnia treatment market, highlighting the potential for new drug sales performance in this sector [20][32]. Core Insights - The insomnia treatment market in China is characterized by a significant unmet need, with over 200 million individuals estimated to suffer from insomnia symptoms, representing a large consumer market potential [16][24]. - The report emphasizes the shift towards innovative insomnia medications, particularly focusing on new types of benzodiazepine receptor agonists (BZRAs) and dual orexin receptor antagonists (DORAs) as key areas for development [25][38]. - The introduction of new drugs like JY-202 (地达西尼) and DORA medications is expected to reshape the market dynamics, with a forecasted rapid increase in market share and sales [34][39]. Market Overview - The insomnia drug market in China has seen stagnant growth due to a lack of new effective treatments, with the market size in 2023 estimated at 31.62 billion yuan [24]. - The report outlines the historical sales performance of major insomnia medications, indicating a long gap since the last new product launch in 2007, which has contributed to the current market stagnation [24][25]. - The report projects a significant increase in the market size and sales for innovative insomnia drugs, particularly with the anticipated approval and market entry of new products [34][39]. Drug Development Trends - The report identifies two main directions for insomnia drug innovation: improvements on existing BZRAs and the development of DORAs, which are expected to have lower addiction risks and better patient compliance [25][38]. - The new drug JY-202 is highlighted for its selective action on the GABAA receptor, which may reduce side effects associated with traditional insomnia medications [34]. - The report also notes the successful clinical trial results for DORAs, which have shown significant improvements in sleep quality without the risk of addiction, making them suitable for broader consumer use [38][39]. Key Players and Recommendations - The report suggests focusing on companies like 京新药业 (JY-202) and 先声药业 (DORA medications) as they are positioned to capitalize on the emerging market opportunities in insomnia treatment [34][39]. - It recommends monitoring the sales performance of these new drugs as they enter the market, particularly in the context of changing consumer behavior and increasing awareness of sleep health [20][32].

China healthcare Global Markets Research EQUITY: HEALTH CARE & PHARMACEUTICALS Our thoughts on year ahead 2026 Innovation, that helps Chinese firms go overseas, remains the key theme What is our take on recent sector softness? It is more sentimental than fundamental Over the past three months (early Sept to early Dec), the healthcare sector has lagged the broader market in terms of share price performance. We note that the CSI 300 Health Care index has declined 12% vs CSI 300 up 3%, while the MSCI China Hea ...

10% 医药生物 沪深300 医药生物行业 -5% 0% 5% 10% 医药生物 沪深300 超配（维持） 医药生物行业双周报（2025/12/5-2025/12/18） 29 省耗材联盟集采启动 投资要点： 本报告的风险等级为中高风险。 本报告的信息均来自已公开信息，关于信息的准确性与完整性，建议投资者谨慎判断，据此入市，风险自担。 请务必阅读末页声明。 行 业 研 医药生物（申万）指数走势 -35% 资料来源：iFind，东莞证券研究所 -40% -20% 0% 20% 22-03 22-05 22-07 22-09 22-11 23-01 23-03 相关报告 -30% -25% -20% -15% -10% -5% 0% 5% 10% 医药生物 沪深300 -35% -30% -25% -20% -15% -10% 5% -35% -30% -25% -20% -15% -10% -5% 0% 医药生物 沪深300 -35% -30% -25% -20% -15% -10% -5% 0% 5% 10% 医药生物 沪深300 2025 年 12 月 19 日 分析师：谢雄雄 SAC 执业证书编号： S0 ...

迈瑞展区内人头攒动，启元大模型、瑞影、瑞检等系列产品正进行现场演示，工作人员讲解产品特性， 吸引了众多观众咨询交流；西门子医疗展区内，几台磁共振成像设备静静陈列，专业讲解员围绕设备的 临床应用场景、影像清晰度提升等核心优势展开介绍，让观众近距离感受高端医疗装备的科技魅力。 一批AI药械、手术机器人领域的产品引人关注。精锋医疗展示了其自主研发的多孔腔镜手术机器人、 单孔腔镜手术机器人、支气管镜手术机器人等丰富完整的产品组合，并为观众演示精细的手术画面。粒 影科技发布的AI+药械研发公共服务平台，深度融合"AI蛋白质结构预测与设计""AI底盘细胞改造"等多 项自研核心技术，可将传统需数年的研发周期缩短至数月。 药械产值1576亿元 12月18日，2025深圳国际高性能医疗器械展暨创新医药展在深圳会展中心举行。此次展会设置了医学影 像及放疗、医学检验、应急救治及康复、人工智能及机器人、创新医药、供应链等"8+1+1"十大展区， 吸引了300余家全球医药与医疗器械领域的领军企业和机构参展，展示千余件创新产品，涵盖高端医疗 器械、创新药、生物制造、AI+药械、消费医疗、核心零部件等深圳乃至国内药械领域的最新成果，为 医 ...

增持前，李西廷未直接持有公司股份，通过Smartco Development Limited间接控制公司股份327,072,335股，占公司股份的26.98%；其一致行动人徐航通过 Magnifice (HK) Limited间接控制公司股份296,951,000股，占公司股份的24.49%，即增持前李西廷及其一致行动人合计控制公司624,023,335股，占公司股份的 51.47%。增持后，李西廷直接持有公司股份1,005,381股，Smartco Development和Magnifice (HK)持有公司股份情况未变，李西廷及其一致行动人合计控制公 司股份625,028,716股，占公司股份的51.55%。 公告显示，2025年11月27日，深圳迈瑞生物医疗电子股份有限公司披露计划增持公告，公司实际控制人之一、董事长李西廷，基于对公司内在价值认可和未 来持续发展信心，践行促进资本市场高质量发展社会责任，计划自2025年11月27日起6个月内，通过集中竞价交易方式增持公司股份，拟增持金额为2亿元 （含交易费用）。 2025年12月12日，李西廷提前完成本次增持计划。2025年11月27日至2025年12月 ...

（编辑 任世碧） 证券日报网讯 12月18日，迈瑞医疗在互动平台回答投资者提问时表示，2025年前三季度，公司营收达 258.34亿元，净利润75.70亿元。前三季度国际业务占公司整体收入的比重已经超过了一半，随着持续深 入的本地化平台建设，未来几年国际收入占整体收入的比重将不断提升，尤其发展中国家将维持快速增 长的趋势，并且伴随收入结构中高端客户占比持续提升，国际业务的盈利水平有望稳步提升。通过提高 试剂核心原料自制率、提升高毛利业务和高端客户收入占比，以及发展中国家持续高增长，公司有能力 在一个竞争激烈的环境中维持较高的盈利水平，同时确保各业务线的市场份额进一步扩大。 ...

证券日报网讯12月18日，迈瑞医疗（300760）在互动平台回答投资者提问时表示，截至2025年9月30 日，公司股东总数为108835户。 ...

Group 1 - The core viewpoint of the article highlights that despite a significant drop in the stock price of Mindray Medical, its actual controller, Li Xiting, has recently increased his stake by approximately 200 million yuan, which is relatively minor compared to previous large-scale reductions [1] - Since the beginning of 2023, Li Xiting and his holding platforms have significantly reduced their stakes, cashing out around 2.5 billion yuan in a single quarter, totaling over 10 billion yuan [1] - Industry insiders believe that the domestic medical and consumables procurement continues to face challenges, and the fundamental aspects of the industry have not yet bottomed out, while overseas operations are facing tariff-related risks [1] Group 2 - As of June 2023, the four holding platforms still collectively held 50 million shares of Mindray Medical, but by June 2025, they are expected to disappear from the list of the top ten shareholders [2] - The estimated cash-out amount from these reductions over the two-year period could exceed 10 billion yuan based on average stock prices [2]

对于迈瑞医疗未来经营和业绩，业内人士认为，国内医疗、耗材集采持续，行业基本面并未见底，而 海外主要业务地区面临关税相关风险。也有分析人士判断，经过四年调整，该公司无论是股价，还是 基本面都有可能迎来反转。 半月增持占总股本不到千分之一 本文字数：1612，阅读时长大约3分钟 作者 | 第一财经 李隽 股价跌破200元大关，相比近500元的历史高点，迈瑞医疗（300760.SZ）的股价，目前已经"膝盖 斩"。 面对股价持续下挫，迈瑞医疗实际控制人李西廷，从11月底开始，在两周多时间内出手增持了约2亿 元的股份。 增持金额虽然不小，但相较于此前减持却显得颇为微弱。2023年以来，李西廷等人控制的持股平台 就大举减持，曾经一个季度就套现大约25亿元，合计已经减持套现过百亿元。 2025.12. 18 根据迈瑞医疗公告，11月27日至12月12日，李西廷使用资金2亿元，累计增持该公司100.5万股，占 公司总股本0.08%的股份，。由于增持已经完成，原定六个月的增持期提前结束。 增持完成后，李西廷其与一致行动人Smartco Development、Magnifice(HK)等，合计持有迈瑞医 疗6.25亿股，占比5 ...